- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00765921
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
December 1, 2016 updated by: Massachusetts Eye and Ear Infirmary
A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
The purpose of the study is to investigate the safety and tolerability of the anti-VEGF (vascular endothelial cell growth factor) treatment, ranibizumab, in combination with proton beam irradiation for the treatment of choroidal melanoma by determining the incidence and severity of ocular adverse events.
Systemic adverse events will also be evaluated.
A secondary objective is to assess the efficacy of ranibizumab in reducing ocular complications that can occur after irradiation.
Study Overview
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts Eye & Ear Infirmary
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with newly diagnosed choroidal melanoma undergoing proton therapy
- Tumors >15 mm in largest diameter and/or >5 mm in height
- Tumors ≤ 15 mm in largest diameter and ≤ 5 mm in height located ≤ 3 mm from optic disc and/or macula, with best-corrected visual acuity 20/100 or better in study eye
Exclusion Criteria:
- History of prior treatment for choroidal melanoma
- Pregnancy or lactation
- Presence of diabetic retinopathy
- History of retinal vascular occlusion or other retinal vascular disease
- Active ocular inflammation or history of uveitis in either eye
- History of uncontrolled glaucoma (defined as intraocular pressure >30mmHg despite treatment with anti-glaucoma medication) or filtering surgery in the study eye
- Previous intravitreal injections of Avastin® in the study eye or in the non-study eye within 30 days.
- Concurrent use of systemic anti-VEGF therapy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1.0 mg ranibizumab
1.0 mg intravitreal injection given bi-monthly for 22 months
|
Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
Other Names:
|
Experimental: 0.5 mg ranibizumab
0.5 mg intravitreal injection given bi-monthly for 22 months
|
Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
incidence and severity of ocular adverse events and systemic adverse events
Time Frame: 12 months and 24 months after initial treatment
|
12 months and 24 months after initial treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
incidence of radiation-induced complications, vision loss and eye loss
Time Frame: 12 months and 24 months after initial treatment
|
12 months and 24 months after initial treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Ivana Kim, M.D., Massachusetts Eye and Ear Infirmary
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (Actual)
February 1, 2016
Study Completion (Actual)
September 1, 2016
Study Registration Dates
First Submitted
October 2, 2008
First Submitted That Met QC Criteria
October 2, 2008
First Posted (Estimate)
October 3, 2008
Study Record Updates
Last Update Posted (Estimate)
December 2, 2016
Last Update Submitted That Met QC Criteria
December 1, 2016
Last Verified
December 1, 2016
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Melanoma
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- 07-06-040
- FVF4384s (Other Identifier: Genentech)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Choroidal Melanoma
-
Aura BiosciencesCompletedOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
Aura BiosciencesActive, not recruitingOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
Jonsson Comprehensive Cancer CenterCompleted
-
Jonsson Comprehensive Cancer CenterCompletedOcular Melanoma | Uveal Melanoma | Choroidal MelanomaUnited States
-
New England Retina AssociatesCompletedChoroidal MelanomaUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
New England Retina AssociatesCompleted
-
Institut CurieCompleted
-
Institut CurieCompletedChoroidal Melanoma, DiffuseFrance
-
Aura BiosciencesTerminatedChoroidal Melanoma | Indeterminate LesionsUnited States
Clinical Trials on ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Instituto de Olhos de GoianiaCompleted